Through a combination of metabonomic, transcriptomic, and molecular biology studies, Chi was verified to resensitize IM-resistant CML cells via the PPARγ/mTOR/PKM2 pathway. Here, MTOR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.